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My research in the lab of Dr. Raoul Kopelman has focused on the synthesis, preparation, 
characterization and in vitro testing of polyacrylamide (PAA) nanoparticles. The Kopelman lab 
has made both positively charged and negatively charged drug-loaded nanoparticles for 
chemotherapy.   
Chemotherapy drug loaded nanoparticles have several intrinsic properties that aid in 
their effectiveness.  First is a targeting ability known as enhanced permeability and retention 
(EPR), which enables the nanoparticles to be delivered and remain at a cancer tumor site with 
selectively, compared to other areas of the body.  Second, the chemotherapy drug release rate 
for polyacrylamide nanoparticles is well suited for a biological system – not too fast as to cause 
release while particles are still in the circulatory system, but fast enough for cytotoxicity after 
contact and entry into cancer cells. 
There are several distinct advantages in using an acrylamide based matrix for the 
synthesis of drug delivery nanoparticles.  First is the biocompatibility and lack of toxicity of the 
nanoparticles, allowing for a reduction of chemotherapy drug side effects and an increase in 
the maximum tolerated dose of the drug.  Second is the great versatility in engineering these 
nanoparticles.  Nanoparticles are highly tunable, allowing for customizability in factors such as 
size, charge, surface characteristics, loaded drug concentrations, and drug release rates.   
While the size of nanoparticles used in our studies are typically on the scale of 30 to 100 





synthesis loading of chemotherapy drugs results in much higher loaded drug concentrations 
within the nanoparticles than when drugs are incorporated during synthesis.  The optimal 
concentration for post-loading of cisplatin was found to be 2 mg/mL, incubated for 4 hours at 
90oC in an aqueous solution.  Binding studies have confirmed that hyaluronic acid (HA) 
conjugated nanoparticles results in greater binding specificity between particles and CD44 
expressing tumor cell lines.  The cytotoxicity of nanoparticles was determined via an MTT assay, 
showing a low degree of toxicity in the case of blank particles and higher toxicity in the case of 
cisplatin loaded particles.  The drug release rates of our nanoparticles were measured using 
release studies and MTT assays, confirming that a polyacrylamide based particle matrix has a 
loaded drug release period of over 1 week.  This drug release profile demonstrates the 
advantage of a polyacrylamide matrix for drug delivery, showing a longer and more stable 
release of loaded drugs than nanoparticle drug formulations currently on the market. 
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At well over 500,000 lives lost per year, cancer is the second most common cause of 
death in the United States1.  Most patients diagnosed with cancer undergo chemotherapy 
treatment; however, some cancer cells are known for their high resistance against 
chemotherapy drugs, so called multi-drug resistance (MDR)2,3.  MDR often leads to relapse in 
cancer patients that have undergone chemotherapy treatment4.  In addition to the 
complications associated with MDR, chemotherapy treatments lead to mild to severe side-
effects in over 80% of patients, including nausea, hair loss, fatigue, increased risk of infection 
and anemia5,6.  These side effects limit the dosages at which chemotherapy drugs may be used 
– a higher dose would more effectively kill chemotherapy drug-resistant cancer cells, but at the 
cost of greater unintended damages to the body.  A strategy to overcome this dose limiting 
issue is localized high-concentration delivery of chemotherapy drugs to sites of cancerous 
growth.  The proposed method of localized delivery that originated and is being studied in the 
Kopelman lab involves the use of drug loaded polyacrylamide based nanoparticles as a 
targeting and delivery system.   
 Current methods of cancer treatment involve an intrusive combination of chemotherapy 
and surgery.  The degree of effectiveness of chemotherapy is directly related to how efficiently 
and effectively the treatment is able to destroy tumor cells while leaving healthy cells 
unharmed.  Current methods of chemotherapy often fall short in terms of 1) being able to 
selectively target tumor cells without harming healthy cells, and 2) being able to effectively kill 





these shortcomings, especially the second, and are thus able to combat tumor cells with 
greater efficiency and efficacy, the field of nanoparticle drug delivery provides further 









 In the 1950’s and 1960’s, the field of pharmaceuticals grew tremendously.  As a result, 
drug delivery and controlled release quickly became a topic of interest.  In 1969, Dr. Peter Paul 
Speiser, a Swiss researcher working at the Swiss Federal Institute of Technology, worked to 
develop drug delivery systems, including polyacrylic acid beads, microcapsules, and eventually 
the first nanoparticle for drug delivery9,10.  Speiser first tested the retarded release properties 
of nanoparticles through delivery of vaccines that generally required multiple injections in 
order to build up a high enough level of antibodies.  He hoped to show that the slow release 
rate properties of nanoparticles would require only a single injection in place of many injections 
Figure 1: Schematic diagram of a molecularly targeted, 
multifunctional PAA NP with the many options applied so far for 







of the pure compound.  In his lab was developed the technique of micelle polymerization, 
where surfactant is added in high concentrations to an aqueous phase, allowing a micelle 
environment in which monomers can polymerize.  This same method is still used to this day for 
nanoparticle production9,11. 
 In the late 1970’s and 1980’s, nanoparticle research began its focus on cancer therapy, 
with studies showing higher chemotherapy drug delivery efficiency with lower toxicities.  In 
1983, Grislain et al. demonstrated rapid clearing of 200 nm diameter nanoparticles from the 
blood stream following intravenous injection, with progressive accumulation in the primary 
tumor location of a Lewis Lung Carcinoma and in lung metastases12.   This same effect was later 
observed and named in 1989 by Maeda and Matsumura as the enhanced permeability and 
retention (EPR) effect2,13.   
 Due to the rapidly dividing nature of tumor cells, the nutrient diffusion-limiting size of a 
tumor is ~2 mm3.  Past this size, the tumor must recruit the formation of new vasculature in 
order to deliver adequate levels of nutrients for further growth.  This often results in the 
formation of defective, or “leaky,” vasculature surrounding the tumor due to the rapid 
vascularization needed to support tumor growth.  These vasculature abnormalities result in 
extensive leakage of blood plasma components, including nanoparticles, into the tumor tissue.   
In addition, tumor vascularization results in poor lymphatic drainage.  These two factors result 
in what is known as the EPR effect7,14.   
 Through the EPR effect, it is possible to achieve concentrations of polymeric drugs 10-50 





molecular weight drugs are not affected by the EPR effect due to their high rate of diffusion, 




Figure 2: (a) Shows the diffusion of a low molecular weight (Mw) drug (black spots) in (i) and a high Mw drug (green spots 
with yellow circles) in (ii), from the blood vessels into the interstitium of tumor tissue (large pink circles). Note that low Mw 
drugs can diffuse freely in and out of the tumor blood vessels because of their small size and, hence, the effective 
concentration of the drug in the tumor diminishes after 1 h when the drug concentration in plasma becomes low (a; i), 
whereas the high Mw drug cannot easily diffuse back into the blood stream because of its large size. Thus, there is 
progressive accumulation of macromolecular drug in the tumor tissues with time by the enhanced permeability and 





 In 2005, Abraxane became the first Food and Drug Administration (FDA) approved 
nanoparticle to enter the commercial market.  Abraxane is a human serum albumin based 





Abraxane has shown great promise for the clinical application of nanoparticle drug delivery, 
performing very well in comparison to its free drug counterpart.  In comparison to patients that 
underwent chemotherapy, a recent Metastatic Pancreatic Adenocarcinoma Clinical Trial 
(MPACT) study showed a 59% increase in the 1 year survival and doubling of the 2 year survival 




Figure 3: Albumin-bound paclitaxel. (Abraxane.pcdem) 
 
 With the current rise in clinical usage of nanomedicines, we can expect a continued 
growth and emphasis of nanoparticle drug delivery.  The research goal of the Kopelman lab is to 
approach the field of nanoparticle drug delivery of chemotherapy agents from the perspective 





of an acrylamide primary monomer.  There are a several key advantages in using an acrylamide 
based matrix that makes it promising for chemotherapy drug delivery.  
A primary advantage for the use of a polyacrylamide matrix is the low toxicity of 
acrylamide polymers, allowing for a high degree of biocompatibility.  Although acrylamide in its 
monomeric form is a neurotoxin and carcinogen, polyacrylamide is not toxic.  In addition, 
polyacrylamide in the presence of a cross-linker is very stable and can easily withstand 
physiologically relevant conditions without risk of degradation into monomers4,16,17.   
A second key advantage of an acrylamide matrix is its high engineerability.  Due to the 
synthetic nature of these particles, their size can be tuned within a very broad range, from 
below the tens of nanometers in diameter upward.  In addition to size, the charge of the 
nanoparticle can also be controlled by the composition of the matrix.  In the Kopelman lab, two 
main types of particles are most commonly synthesized: positively charged nanoparticles 
containing N-(3-Aminopropyl)methacrylamide (APMA) as the secondary monomer and 
negatively charged nanoparticles containing acrylic acid (AA) as the secondary monomer.   
In addition to size and charge, the surface characteristics of these particles can be 
adjusted as well, conjugating various ligands to affect the physical and chemical characteristics 
of the nanoparticle.  Nanoparticle surface conjugation is performed for various reasons, 
depending on the ligand being used.  Hyaluronic acid (HA) is a ligand for the CD44 cell surface 
antigen, and is conjugated onto the surface of nanoparticles for increasing the selectivity of cell 





such as HA do not increase the localization of nanoparticles to the tumor site due to the EPR 
effect, it does increase the internalization of the nanoparticle18. 
 
 
Figure 4: Targeting strategies for cancer therapy. Passive targeting can be achieved by enhanced permeation and retention, 
an effect involving leaky vascular structures. Active targeting mediated by targeting ligands specifically localizes drug carriers 





HA is used to target the CD44 cell-surface glycoprotein, which is overly expressed in 
many cancer cell lines, including the Hep3B and SKOV3 ovarian tumor cell lines19,20,21.  HA 
conjugation results in an overall increase in negative charge on the nanoparticle surface, 
causing electrostatic repulsion of the particle from the cell surface and a slower rate of 
internalization in comparison to positively charged particles.  However, due to the CD44 
antigen’s strong affinity for binding HA, surface conjugation of HA onto nanoparticle results in 





example of specific binding interactions between the nanoparticle and the targeted cell, which 
also overcomes the global charge repulsion.   
In contrast to the negatively charged HA ligand, another commonly used ligand for 
assisting nanoparticle conjugation is the neutrally-charged polyethylene glycol (PEG).  The 
development of covalently attached PEG chains onto the surface of nanoparticles began in the 
1980’s and 1990’s.  Because nanoparticles are rapidly removed by macrophages in the 
reticuloendothelial system, their circulation time in the body is relatively short.  Attachment of 
PEG onto the surface of nanoparticles, however, greatly reduces the rate by which they are 
eliminated in the body by neutralization of nanoparticle surface charge, creating a hydrophilic 
outer shell and thus reducing the particle surface charge interactions with the cellular 
membrane.  This charge neutralization, along with steric repulsions from the large chain 
lengths, make PEG an effective “stealth agent” when conjugated onto the surface of 
nanoparticles9,22.  This is useful for applications where particle-cell interactions are unwanted, 
such as when particle clearance via the reticular-endothelial system needs to be minimized23.  
For example, PEG coated Fe3O4 nanoparticles has been shown to reduce nonspecific uptake of 
the particle by macrophage cells and was shown to produce negligible aggregation under cell-











In addition to surface conjugation, acrylamide nanoparticles can be loaded with a broad 
range of molecules.  Commonly loaded chemicals used in the Kopelman group are 
chemotherapy agents such as cisplatin and docetaxel.  In addition, imaging agents may also be 
loaded or directly incorporated into the matrix of nanoparticles.  For example, rhodamine 
containing nanoparticles are commonly used as a method of fluorescently tagging nanoparticles 
to study cell binding.   
 While a variety of small molecule drugs can be loaded into nanoparticles for delivery, 
cisplatin has been selected as a drug of choice in our studies for several reasons.  First is its 





focus of our cell studies.  Second is that it is 
a small molecule which exhibits fast 
delivery characteristics.  The dosage of the 
drug is limited by its toxicity to the kidneys 
and nervous system, as well as a variety of 
side effects, including nausea, hearing loss, 
electrolyte disturbance, and anemia25.  The dose limiting aspect of cisplatin makes it a perfect 
candidate for nanoparticle drug delivery, which would not only allow for localized delivery of 
the drug to the tumor site but also a reduction of side effects as a result of the targeted 
delivery.  Lastly, the platinum present in cisplatin allows for easy and accurate characterization 
of drug loaded nanoparticles via inductively coupled plasma – optical emission spectroscopy 
(ICP-OES).   
 In addition to cisplatin, docetaxel is 
another common drug candidate for 
nanoparticle delivery.  Mainly used for the 
treatment of ovarian, breast, prostate, and 
lung cancers, docetaxel interferes with cell 
mitosis26,27,28.  Due to its mechanism of 
action, docetaxel affects cells in the body that have a high turnover rate, resulting in slow 
division of hair follicles, bone marrow, and other rapidly dividing cells in addition to tumor cells.  
For these reasons, localized nanoparticle delivery of docetaxel could avoid these germ cells, 
directing the drug to the tumor site.   
Figure 6: Chemical structure of cisplatin. 





The rate at which these loaded chemicals are released is also highly tunable.  The 
degree to which the nanoparticle is held together is largely determined by the ratio of cross-
linkers to monomers.  Fewer cross-linkers in the nanoparticle matrix result in a faster rate of 
release4,16,17.  Nanoparticles contain cross-linkers that cleave under specific conditions, causing 
drug release.  In the case of 3-acryloyloxy-2-hydroxy-propyl methacrylate (AHM) cross-linked 
nanoparticles, the cross-linker is cleaved by esterase.  N,N’-Bis(acryloyl)cystamine (CBA) cross-
linked nanoparticles are redox sensitive and cleave in the presence of a reducing agent such as 
glutathione (GSH) or dithiothreitol (DTT).  Each molecule of AHM contains two ester bonds that 
can be readily cleaved by esterase while CBA contains a disulfide bond that is readily reduced to 










Following synthesis, several key analytical instruments are used for the characterization 
of our nanoparticles.  Characterization of nanoparticles includes determination of size, surface 
charge, and total loaded drug content.  These are determined via dynamic light scattering (DLS), 
electrophoretic light scattering (ELS), and ICP-OES, respectively. 
The Beckman Coulter DelsaNano C is the primary instrument used for both particle 
sizing and surface charge determination.  Particle sizing is accomplished using dynamic light 
scattering, measuring the rate of fluctuations in a laser that is passed through the sample.  As 
light is passed through the sample, the photons are scattered in all directions via Rayleigh 
scattering.  As the particles diffuse in the solution, the scattered photons constructively and 
destructively interfere with those from surrounding particles.  The intensity of this scattering 
undergoes a time-dependent fluctuation due to the motion of the particles in the sample.  
Fluctuations at a higher frequency are due to smaller particles while lower frequency 


















Surface charge is accomplished using electrophoretic light scattering (ELS) to calculate 
zeta potential.  In ELS, the velocity of particles is determined in a similar fashion as in DLS, but 
under an applied electric field.  As charged particles move through the sample solvent, a laser is 
passed through the sample.  The frequency of the scattered light is detected, and the Doppler 
shift between the laser light and the scattered light is measured to determine the velocity of 
the particle.  Since the velocity of the particle in an electric field is proportional to its charge, 










Total encapsulated cisplatin content is determined via ICP-OES, using an yttrium internal 
standard.  Platinum concentrations are determined, corresponding to total cisplatin content of 
a nanoparticle.  ICP-OES is an excellent method of detecting trace metals, such as platinum, 
owing to its low limit of detection and high degree of reproducibility.  In ICP-OES, argon plasma 
is used to produce excited atoms and ions.  These atoms and ions then emit incidental photons 
of a wavelength specific to each element, and the wavelength and intensity of the light is used 
to determine the type of element and its concentration within the sample33. 
Following the physical characterization of the nanoparticle, several in vitro tests are 
performed to determine the binding efficiency and cytotoxicity of the particles.  In surface 
binding studies, cells are incubated in a solution of fluorescently tagged nanoparticles for 
several hours.  After incubation, excess nanoparticles are rinsed away and the cell wells are 
measured for fluorescence output.  Thus, groups of cells with a higher fluorescence correspond 





nanoparticles to the cellular membrane eventually leads to endocytosis and internalization of 
the particle.   
 In addition to confirming nanoparticle surface binding, 3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assays are used to determine the efficacy of nanoparticle 
drug delivery and to measure the overall cytotoxicity of particles.  MTT assays measure the 
enzymatic activity of cells which reduces a soluble tetrazolium containing dye into a purple 
colored and insoluble formazan containing dye (figure 11)34. Rapidly dividing cells, such as 
cancer tumor cells, show a high degree of metabolic activity and thus show a high degree of 
MTT reduction.  MTT is metabolized to its formazan product by accepting electrons from a 
cellular reducing equivalent such as NADH, NADPH, or succinate.   This redox reaction is 
dependent upon the redox activity and mitochondrial function of the cell, indicating the cellular 
oxidative metabolic activity35. 
 
 
Figure 11: Reduction of a tetrazolium dye, 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT), into a 







Upon addition of MTT, a greater concentration of viable cells within a well result in 
greater conversion of MTT into the colored formazan dye.  The high absorptivity of the 
formazan dye at 570 nm is then measured using a 96 well microplate reader to determine the 
concentration of cells alive at the time of the assay.   
  MTT assays are carried out following the incubation of cells with drug containing 
nanoparticles to test for drug delivery efficacy.  Drug loaded nanoparticles are typically 
compared against non-loaded nanoparticles to ensure low particle cytotoxicity.  In addition, a 
solution of the free drug is also used to compare the cytotoxicity of the drug loaded 
nanoparticles versus that of the unloaded drug.   
 In summary, we aim to create a robust and biocompatible nanoparticle platform that 
can selectively deliver a chemotherapy agent to the tumor site.  Nanoparticle drug delivery is 
advantageous when compared to direct delivery of the drug in that it can prolong the 
timeframe of the effectiveness of the drug and can be directed to the tumor site via the EPR 
effect and selective targeting.  Polyacrylamide nanoparticles are advantageous in that they are 
biocompatible and nontoxic.  In addition, polyacrylamide nanoparticles are highly engineerable, 





Materials and Methods 
 
Synthesis of Polyacrylamide Based Nanoparticles 
Add 0.269 g AHM cross-linker and 0.539 
g acrylamide to 2 mL of cisplatin solution.  
Additionally, add a desired amount of APMA 
(positively charged) or AA (negatively charged) 
secondary monomer, based on the properties 
you wish for your particles to have.  Sonicate 
the solution for 5 minutes, and heat if 
necessary, until all cisplatin has dissolved. 
In a 100 mL round bottomed flask, add 
1.6 g of dioctyl sodium sulfosuccinate (AOT), 3.3 
mL of Brij 30, and 45 mL of argon purged 
hexanes.  Introduced a stir bar and rubber 
septum to the flask, and place it under an argon 
atmosphere, with argon bubbling out of 
solution.  Stir for 20 minutes. 
 
Figure 12: Reverse micelle polymerization reaction setup 






Sonicate the monomer solution for an additional 5 minutes, and transfer its contents to 
the round bottomed flask with a syringe.  As cisplatin is sensitive to light, cover the reaction 
flask with foil, and continue stirring for 20 minutes. 
Add 0.1 mL of 10% aqueous ammonium persulfate solution (APS) (w/v) and 0.1 mL of 
tetramethylethylenediamine (TEMED) to the round bottomed flask.  Pull the argon purge 
needle from out of the solution, but still on the flask.  Let the solution stir for 2 hours.   After 2 
hours, the solution should appear slightly milky white.  Remove hexanes with rotary 
evaporation.  The solution should now be viscous and milky white.   
 
Figure 13: Rotary evaporation of polymerized nanoparticle reaction flask.  The solution becomes milky white and viscous as 






Wash nanoparticles via 300 kDaMWCO 
Amicon ultrafiltration cell, five times with 
ethanol and five additional times with water.  
This is to ensure removal of all surfactant and 
unreacted monomers.  Freeze-dry washed 
nanoparticle solution via liquid nitrogen and 




Post-Loading of Cisplatin 
 To 1 mL of H2O is added 2 mg of cisplatin.  The solution is sonicated until all cisplatin has 
been dissolved.  10 mg of nanoparticle is added to the solution, allowed to dissolve, and then 
stirred at 90oC for four hours.  After incubation, wash nanoparticles via 100 kDaMWCO Amicon 
ultrafiltration cell seven times with water to ensure all free cisplatin has been washed away.   
 
 






Conjugation of Nanoparticles with Hyaluronic Acid 
 
Figure 15: Reaction scheme for HA conjugation of cisplatin loaded nanoparticles. 
 
 Dissolve 8.5 mg of HA in 1 mL of pH 7.4 PBS.  After all HA has been dissolved, add 10 mg 
of drug-loaded nanoparticles and allow the solution to stir for 2 hours at room temperature.   
After reaction for 2 hours, wash nanoparticles via either a 300 kDaMWCO Amicon ultrafiltration 
cell (when reacted with 90 kDa HA) or a 100 kDaMWCO Amicon Centrifugal filter unit (when 
reacted with 17 kDa HA).  Wash seven times with PBS.  Nanoparticles may then be freeze-dried 
to collect solid particles or maintained in a solution of PBS.  
  
Methods of Analysis 
Particle Sizing via dynamic light scattering (DLS): The size of nanoparticles is determined using 
a 2 mg/mL aqueous solution and a Beckman Coulter Delsa Nano C set to DLS. 
Surface Charge Measurements via electrophoretic light scattering (ELS): The surface charge of 
nanoparticles is determined using a 2 mg/mL aqueous solution and a Beckman Coulter Delsa 






Figure 16: Beckman Coulter Delsa Nano C used for DLS and ELS measurements. 
 
 
Encapsulated Drug Concentrations via inductively coupled plasma optical emission 
spectroscopy (ICP-OES):  Nanoparticles solutions are prepared using PBS, with a particle 
concentration of 1 mg/mL.  To 1 mL of nanoparticle solution is added 0.25 mL of 20 ppm 
yttrium stock solution in 5% HNO3, and 3.75 mL of 5% HNO3.  A blank is made as control, 
containing PBS in place of nanoparticle solution.  The ICP is set to monitor two emission 
wavelengths, 371.029 nm for the yttrium standard, and 265.945 nm for determination of 
platinum concentrations.  Samples are fed through the ICP, and cisplatin concentrations are 






Figure 17: ICP-OES system used for detection of cisplatin concentrations. 
 
 
Drug Release Studies 
Dissolve 1 mg of cisplatin loaded nanoparticles into 1 mL of PBS with a cleaving agent 
specific to the cross-linker.  Incubate and stir the samples at 37°C, taking multiple nanoparticle 
incubation time points.  Remove each sample after allotted incubation time and filter out 
nanoparticles using a 100 kDaMWCO Amicon ultrafiltration cell, keeping the filtrate.  The 
filtrate is prepared for ICP-OES using the method outlined above.  Measure cisplatin 







 Synthesize rhodamine containing nanoparticles using the normal particle preparation 
procedures (see above), but adding rhodamine 6G tetrafluoroborate into the initial monomer 
solution and replacing acrylic acid with N-Hydroxysuccinimide (NHS) conjugated acrylic acid.  
After synthesis with rhodamine, conjugate nanoparticles with hyaluronic acid (HA), using 1-
Ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) as a cross-linker.   
 Next, transfer cells into a 96 well plate and allow settling overnight.  After incubation 
overnight, add 50 μL of 2 mg/mL nanoparticle solution into each well and allow incubation for 4 
hours.  After 4 hours, remove the nanoparticle solution from each well, and measure the 
fluorescence of cells, using a microplate reader. 
 
Cell Studies 
 Using a hemocytomer, determine the concentration of tumor cells to be tested.  Dead 
cells are excluded from counting using trypan blue staining.  Introduce tumor cell line to 96 well 
cell culture plate at approximately 3000 cells per well, and allow for them to grow overnight 
with incubation at 37 °C. 
 Prepare cell media containing either drug loaded nanoparticles or free cisplatin.  





condition.  Typically, 12 wells are tested for each condition, allowing for 8 conditions to be 
tested.  Allow cells to incubate at 37°C for 2 days. 
After incubation, remove the nanoparticle/cisplatin containing solution from the wells 
and add fresh fetal bovine serum (FBS) free cell media with 0.83 mg/mL thiazolyl blue 
tetrazolium bromide. Incubate cells at 37°C for 4 hours. 
After 4 hours, remove the solution from the wells and add 100 μL dimethyl sulfoxide 
into each well.  Absorbance is measured at 550 nm with a background of 610 nm, using a 






Results and Discussion  
 
General Characteristics of Polyacrylamide Nanoparticles 
Synthesis of nanoparticles is accomplished via water in hexane polymerization, allowing 
for size control and uniformity of particles.  Monomers and cross-linkers are soluble in the 
water phase, and react in nano-sized aqueous micelles formed as the solution is stirred in the 
oil phase.   
Synthesis of nanoparticles can be accomplished with or without initial drug 
incorporation in the water phase.  If cisplatin is not included in the synthesis of the 
nanoparticles, it is loaded afterward.  This typically results in a higher loading efficiency as well 
as a greater total weight percent of the drug.  Post loading of cisplatin is often performed at 
high temperatures (90oC) in order to increase the loading speed and decrease incubation time.  
Cisplatin has been shown to maintain its cytotoxicity after incubation at these temperatures.   
The ratio of water to hexane will determine the nanoparticle size by alteration of the 
aqueous micelles.  Both the ratio of monomers to cross-linker as well as particle size affects the 
release rate of loaded drugs.  Smaller particles, which have a higher surface area to volume 
ratio, are able to release drugs at a much faster rate than larger particles.  In addition, particles 








Figure 18: Representative synthetic scheme for APMA, AHM cross-linked polyacrylamide based nanoparticles with initial 
drug incorporation. APS and TEMED act as catalysts for polymerization, and water/hexane reverse micelles are used in the 
size control of nanoparticles. 
 
Nanoparticles are characterized via determination of particle size, surface charge, total 
encapsulated cisplatin content, and cisplatin release profile.  Particle sizing is determined by 
measurement of a 2 mg/mL aqueous nanoparticle solution in a DLS spectrometer.  While typical 
particle sizes are on the order of tens to hundreds of nanometers, monodisperse particles with 
a Gaussian distribution in the size range of 30 to 100 nm are used for our in vitro cell studies.  
Nanoparticles are typically sized following surface conjugation, as well, which results in an 







Figure 19: Representative particle sizing data for AHM cross-linked acrylamide-APMA nanoparticles, measured via Beckman 
Coulter Delsa Nano C particle analyzer. 
 
Surface charge is determined by ELS.  The surface charge of the particle is dependent 
upon what specific secondary monomer is used in its preparation.  In the case of an acrylamide-
APMA matrix, the positive charge is due to the amine moiety present on APMA.  The 
acrylamide-acrylic acid (AA) matrix is negatively charged due to the carboxylic acid moiety 
present in acrylic acid.  Following surface conjugation with HA, APMA particles become more 
negative in charge and AA particles remain negative.  Conjugation with PEG results in charge 
neutralization for both APMA and AA nanoparticles.  Below shows typical results for surface 






Figure 20: Representative particle ELS data for AHM cross-linked acrylamide-APMA nanoparticles, measured via Beckman 
Coulter Delsa Nano C particle analyzer. 
 
 
Surface charge is an important factor in determining the stability of nanoparticles as 
well as determining how the particle interacts with the cell membrane.  Charged surfaces 
increases the repulsive interactions between nanoparticles, leading to less aggregation of the 
particles when dissolved in solution.  Suspensions of nanoparticles have been shown to be 
stabilized when the minimum absolute zeta potential of the particles is ± 30 mV.  However, 
while PEG conjugation decreases the overall charge of the particles, the steric effects and 
hydration forces of adding a bulky polymer to the particle surface tends to increase overall 
stability of particles, as well18. 
 Prior to HA conjugation, cisplatin is loaded into blank nanoparticles using the post-
loading method described above.  In order to quantify cisplatin concentration of nanoparticles, 





shows typical platinum concentrations present in post-loaded nanoparticles, using various post-
loading conditions.   
 
  
 Cisplatin solution 
concentration stir time wt% loading 
loading 
efficiency, % Solution condition 
1 0.5mg/mL overnight 1.7 33 Clear 
2 0.5  mg/mL 4 hrs 1.9 37 Clear 
3 1 mg/mL 4 hrs 3.8 38 Clear 
4 2 mg/mL 4hrs 11.5 58 clear 
5 2.91 mg/mL 4 hrs 6.1 21 not suspendable 
 
Figure 21: Platinum concentration and loading efficiency in cisplatin loaded AHM nanoparticles.  All concentrations were 
determined via ICP-OES. 
 
 
 Typical loading efficiencies for nanoparticle are ~30-60%, with a maximum loading 
efficiency at 2 mg/mL cisplatin during the post loading.  Since post loading is carried out in 
aqueous conditions, cisplatin’s limited solubility in water restricts the amount which may be 
dissolved in the reaction solution.  As a result, cisplatin concentrations higher than 2 mg/mL will 
become turbid unless the reaction is heated.   Loading efficiency reaches a maximum around 4 







Drug Release Studies 
 
Following the synthesis, drug loading, surface conjugation, and characterization of 
nanoparticles, drug release studies are performed to study the rate at which the loaded drug is 
released into the environment.  Drug release studies are performed at biologically relevant pH 
and temperatures, and typically five data points are taken over a week-long time frame.   Drug 
loaded nanoparticles are first dissolved in each of the PBS solutions containing cross-linker 
activators (DTT, GSH, or esterase) at intercellular concentrations.  Additional samples that do 
not contain the activator serve as controls.  These samples are then stored at 37oC until their 
respective time points.  The samples are then filtered through an Amicon centrifugal unit to 
remove nanoparticles, and the drug concentration in the filtrate is determined.  Figure 22 
shows typical results for the release profile of cisplatin loaded, AHM cross-linked nanoparticles 
over a period of one week.  The importance of nanoparticle cross-linkers is twofold in nature: 
To stabilize the acrylamide matrix while the nanoparticles are circulating in the bloodstream, 












 One of the key advantages of using an acrylamide matrix for nanoparticle drug delivery 
is the stability of cross-linked polyacrylamide.  This high stability results in a much slower drug 
release rate (order of 1 week) than the rate of vascular circulation and cell binding (order of 1 
hour), allowing for the targeted delivery of the nanoparticles and steady release of the loaded 







Cell Binding Studies 
Binding studies are used to determine the degree of specificity to which a nanoparticle 
will bind to a specific cell surface protein.  In the case of HA coated nanoparticles, the HA 
ligands are used to target cells that have a high expression of the CD44 cell-surface 
glycoprotein.  Figure 23 shows the results of a binding study in which two cell lines, one with 
high CD44 expression (Hep3B) and one with low CD44 expression (HepG2), were incubated with 
HA conjugated and non-conjugated nanoparticles which contain rhodamine dye, a strong 
fluorophore.   
 
Figure 23: Binding study results using negatively charged nanoparticles. HA = Hyaluronic acid coated nanoparticles.  NP = 
Non-coated nanoparticles. 3B = Hep3B cells (High CD44 expression).  G2 = HepG2 cells (Low CD44 expression).  Y-axis shows 
the relative number of bound nanoparticles per cell.  3B and G2 data sets were normalized independently. 
 
 
 After incubation, the cells are washed with Dulbecco's Phosphate-Buffered Saline 














cell well to determine the relative amount of cell bound nanoparticles.  Because nanoparticles 
contain the rhodamine fluorophore, more surface-bound nanoparticles results in a greater 
degree of total fluorescence.  In the provided study, HA conjugated nanoparticles preferentially 
bind to Hep3B while binding HepG2 to a far lesser degree.  Non-conjugated nanoparticles did 
not show strong binding to either cell line due to the repulsive forces between the negatively 
charged nanoparticle and the cell membrane.   
 Cell binding studies are carried out using fluorescence spectroscopy and microscopy.  
Depending upon the surface charge and functional groups of a nanoparticle, its binding affinity 
for various cell lines will vary.  In terms of nonspecific binding, positively charged nanoparticles 
will have attractive coulomb interactions with the negatively charged cellular membrane.  This 
attraction allows stronger intrinsic binding between positive nanoparticle and the cell 
membrane, while negatively charged particles are more repelled.  In addition to coulomb 
interactions based upon surface charge, there are also specific interactions between functional 












Cell Toxicity Studies 
 
After characterization of nanoparticles, we employ an MTT assay in order to determine 
cytotoxicity.  A typical assay consists of cell groups introduced to several different growth 
media conditions: cell media containing cisplatin (free molecule), non-loaded (blank) 
nanoparticles, nanoparticles loaded with various concentrations of cisplatin, and media with no 
treatment to serve as a control.  Figure 24 shows typical results for an MTT assay, performed on 
the HEY1 cell line incubated for four hours. 
 
 
In this example assay, the pure cisplatin incubated cells showed a high degree of 
cytotoxicity while the no treatment acted as the control for cytotoxicity.  Cells that were 
Figure 24: Representative results for an MTT assay using the HEY1 cell line, comparing the cytotoxicity of cisplatin loaded 





incubated for four hours with an equivalent concentration of cisplatin loaded nanoparticles 
showed a low degree of cytotoxicity after the incubation period, due to the timed drug release 
rate of polyacrylamide nanoparticles.   Cytotoxicity between in vitro and in vivo studies will also 
differ due to physiological factors not present in the MTT assay.  An example of this is both 
passive and active targeting, which would not be present for free cisplatin but would increase 
the cytotoxicity of cisplatin loaded functionalized nanoparticles.  In addition, nanoparticles used 
for this study did not contain a targeting moiety on the particle surface, which would also 





Conclusion and Future Directions  
 
 The field of nanotechnology has grown rapidly in the past decades and has now 
matured to the point of making an impact within the medical field.  FDA approved nanoparticle 
delivered chemotherapy agents are now available and increasingly used on the medical market, 
with more and more on the way.  The most common types of nanoparticle delivery systems are 
composed of liposomal and protein based matrices, such as Doxil, a lysosome packaged form of 
doxorubicin surrounded by a layer of methoxypolyethylene glycol (MPEG), and Abraxane, an 
albumin packaged form of paclitaxel.  The half-life of Doxil is approximately 55 hours, while that 
of Abraxane is 27 hours, greatly increasing the terminal half-lives of their free drug 
counterparts, 17.9 hours and 69 minutes, respectively36,37.   
While these nanoparticle drug formulations dramatically increase the half-life of the 
chemotherapy agent, the timescale of drug release is still not optimal.  For example, paclitaxel 
is a cytoskeletal drug which targets tubulin, blocking the progression of mitosis, thereby 
preventing cell division and triggering apoptosis or reversion of cells to the G-phase of the cell 
cycle.  As such, paclitaxel is a cell cycle dependent drug.  In the case of carcinoma of the breast, 
it must be administered for several hours every two or three weeks, for four cycles, in order to 
have maximum effect.  Thus, Abraxane’s 27 hour half-life is still very short in comparison to the 
amount of time required to treat breast cancer38,39. 
The research and development of a polyacrylamide based nanoparticles for the purpose 





matrices are durable and stable, allowing for longer circulation time and lower frequency of 
intravenous infusions required throughout the chemotherapy process.   Polyacrylamide is also 
nontoxic and biocompatible, and it can readily withstand physiological conditions without 
degradation. 
In addition to stability, polyacrylamide matrices also offer a higher degree of versatility 
and engineerability, allowing for incorporation of a wide variety of chemical groups upon the 
nanoparticle surface or within the matrix.  For example, fluorescent dyes, such as rhodamine, 
can be readily incorporated into the acrylamide matrix, creating a fluorescent tag for tracking 
and quantification of nanoparticle concentrations.  Surface chemistry is very accessible through 
reaction with the carbonyl site of the secondary monomer (AA or APMA), allowing for covalent 
linkage of ligands that serve a variety of purposes.  Current chemotherapy nanoparticle 
formulations rely solely upon the EPR effect to localize drug delivery to the tumor site.  While 
the EPR effect can greatly increase drug localization, there is a limit to the degree of specificity 
this can offer toward selective targeting of tumor cells.  While the EPR effect draws 
nanoparticles into the tumor site, it does not select for the types of cells that the nanoparticles 
are being taken up by.  In order to make this distinction, targeting moieties that interact with 
specific cell surface proteins are added to the surface of the nanoparticle, leading to greater 
uptake of the nanoparticle when it comes in contact with the specific cell of interest.  This high 
degree of versatility has led to the use of polyacrylamide nanoparticles as both a targeted 





The stability, biocompatibility, and versatility of the polyacrylamide nanoparticle make it 
a promising candidate for chemotherapy drug delivery.  Recognizing this, the Kopelman lab is 
pursing research of a polyacrylamide nanoparticle drug delivery system, with research spanning 
from synthesis of the particles to in vivo studies on tumor cell lines.  Using reverse micelle 
polymerization, a primary acrylamide monomer and other secondary monomers (AA, APMA) 
are linked together with a cross-linking agent (CBA, AHM).  In a hexane solution, nano-sized 
micelles of water and surfactant are formed, and the soluble monomers and cross-linkers react 
to form spherical nanoparticles ranging from 30-100 nm in diameter.  Nanoparticles are then 
loaded with a chemotherapy drug (cisplatin, docetaxel, etc.) and conjugated with a surface 
ligand (PEG, HA, 5-FTSC, etc.), washed to remove any impurities and unreacted molecules, and 
freeze dried to solidity the nanoparticles.  Before release and cell studies, nanoparticles are 
characterized for size via DLS, surface charge via ELS, and internal drug concentration via ICP.  
Drug release studies are carried out to study the release profile of the nanoparticle, testing the 
triggering mechanism of the nanoparticle when its cross-linker in in the presence of its 
respective cleaving agent (AHM via esterase, CBA via glutathione).  Cell binding studies are 
carried out using fluorescently tagged nanoparticles.  Tumor cells are incubated in the presence 
of these nanoparticles, and fluorescence spectroscopy and microscopy is then used to quantify 
the binding efficiency of the particular nanoparticle.  Lastly, cytotoxicity tests are carried out 
using MTT assays. 
 As we move forward with our research on nanoparticle drug delivery of anti-cancer 
agents, there are several projects planned for future studies.  These include testing of 





chemotherapy drugs that might otherwise not be viable without a nanoparticle formulation, 
focusing efforts to target cancer stem cells, as well as overcoming their multi-drug resistance 
(MDR), and testing the use of photodynamic therapy in conjunction with drug delivery. 
Animal studies 
 Following in vitro cell studies, the next logical step for testing nanoparticle efficacy is the 
use of an animal model.  Mouse and rat models provide an effective method of mimicking 
human physiology and allow for pre-clinical testing of our nanoparticles.  Currently, the 
Kopelman lab collaborates with the lab of Dr. Ronald Buckanovich (University of Michigan Ann 
Arbor, Medical School) on animal studies, where intravenous injections of chemotherapy drug 
loaded nanoparticles are tested on mice with ovarian tumors, as well as with the labs of Dr. 
Pedro Lowensein and Dr. Maria Castro on brain tumors.  As the project advances, we plan to 
use animal studies to a greater extent, testing the efficacy of nanoparticles that target different 
types of tumor cells and deliver various types of chemotherapy drugs.  
Other drugs 
 In addition to the use of cisplatin and docetaxel drug delivery, another future direction 
for nanoparticle research in the Kopelman lab is the delivery of other chemotherapy agents 
with high cytotoxicity that would otherwise not be a viable option for use in cancer treatments.  
Many experimental chemotherapy agents are very effective at destroying cancer cells but 
cannot be used for direct injection due to a high degree of toxicity.  Nanoparticle drug delivery 
can potentially overcome this toxicity through localized delivery to the tumor site, greatly 





Cancer Stem Cells 
Cancer stem cells (CSC) are cancer cells that possess the characteristics of normal stem 
cells. They are tumor forming and are the source of all cell types found within a tumor site.  
Similar to normal stem cells, CSCs are self-renewing and differentiate into tumor cells in order 
to initiate and sustain tumor growth.  CSCs have been suggested to be the cause of many 
negative aspects associated with cancer such as MDR and relapse of the disease, as well as 
metastasis.  Many cancer therapies ultimately do not completely eliminate the disease because 
CSCs remain within the body even after tumors have been destroyed, allowing for the eventual 
reemergence of new tumors.  CSCs are more difficult to target than tumor cells for several 
reasons.  First is their ability to remain dormant within the body at a slow metabolic rate, thus 
making them difficult to target using drugs that combat the quick proliferation rates of tumor 
cells.  Second are their high expression levels of drug transporters, DNA mismatch repair 
enzymes, and detoxification enzymes, making them much more resistant to chemotherapy and 






Figure 25: A new treatment strategy that specifically targets cancer stem cells, when 
combined with current treatments, may lead to a more complete and durable 







If CSCs can be directly targeted for destruction, cancer can be much more efficiently and 
effectively eliminated from the body.  As such, targeting CSCs is a highly advantageous method 
toward developing next generation cancer therapies.  The strategy of nanoparticle drug 
delivery used in the Kopelman lab is a promising method for selected targeting of CSCs for 
several reasons.  First is the ability of nanoparticle drug delivery to overcome MDR by bypassing 
or saturating drug elimination pathways of the CSC.  Nanoparticles would be effective at 
overcoming this MDR barrier because nanoparticles deliver high concentrations of the 
chemotherapy drug after internalization into the cell, giving the potential to overpower drug 
elimination and DNA repair pathways of the cell.  Due to the selective targeting ability of 
functionalized nanoparticles, chemotherapy agents can be delivered at concentrations much 
higher than allowed by direct injection of the drug, while eliminating many of the side effects 
associated with the drug40,41. 
Photodynamic Therapy 
 
In addition to drug delivery, nanoparticles can also be designed for photodynamic 
therapy.  An example of this is nanoparticles that contain covalently linked methylene blue.  
These methylene blue moieties are bound to the nanoparticle matrix and are not released.  





When exposed to oxygen and light, methylene blue can create singlet oxygen species.  These 
singlet oxygen species, and the other reactive oxygen species (ROS) they create, are highly 
reactive and are able to interfere with and destroy the cell once the nanoparticle has been 
internalized and activated by light. The combination of targeted chemotherapy drug delivery 
and photodynamic therapy via nanoparticle would be an effective strategy for increasing cancer 
killing efficacy. 
 
Figure 27: Nanoparticles are a flexible platform for the detection and treatment of cancer.  In this example, photodynamic 








As is the case with the majority of medical research, the ultimate goal of this project is 
to be granted drug approval by the FDA so that these polyacrylamide nanoparticles may be 
used on human cancer patients.  After synthesis, in vivo, and animal testing of the 
nanoparticles, the FDA’s initial approval must be granted so as to begin human testing.  The 
drug then enters three phases of clinical trials that are approximately 1, 2, and 3 years long, 



















As cancer research continues to advance, more and more viable options for curing the 
disease begins to appear.  Nanoparticle drug delivery has shown a great degree of promise in 
the past several years, and we believe that polyacrylamide nanoparticles have the potential to 
continue this promising trend, offering new technological advancements to the field of drug 
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